person · Reporting owner

HILLEMAN JERYL L

Disclosed activity across 8 companies

Tapewire entity: 29474
SEC CIK: 0001216628

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CUTERA INCCUTR · Entity 82936	Director	October 24, 2024	November 05, 2024
Intersect ENT, Inc.XENT · Entity 127294	Chief Financial Officer	May 07, 2019	May 08, 2019
Minerva Neurosciences, Inc.NERV · Entity 6245	Director	September 27, 2023	September 29, 2023
NovoCure LtdNVCR · Entity 4494	Director	June 03, 2026	June 05, 2026
Omada Health, Inc.OMDA · Entity 2364	Director	October 05, 2026	October 07, 2026
SI-BONE, Inc.SIBN · Entity 2501	Director	June 04, 2026	June 09, 2026
Talis Biomedical CorpTLIS · Entity 87664	Director	March 16, 2021	March 18, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CUTERA INC

Report date October 24, 2024 · Filed November 05, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.65 · Expires 2031-10-23	Direct	40,000	Reported balance After 2024-10-24 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-10-24 · Grant · Acquired 14,673 · Balance 40,000 F1: All shares vest on the earlier of 12 months from grant date, or on the day of the 2025 annual stockholder meeting, subject to the Reporting Person continuing to be a service provider of the Company. F2: The expiration date is subject to earlier expiration upon the termination of the Reporting Person's service with the Company.

Filing footnotes · ownership attribution and instrument terms

F1: All shares vest on the earlier of 12 months from grant date, or on the day of the 2025 annual stockholder meeting, subject to the Reporting Person continuing to be a service provider of the Company.

F2: The expiration date is subject to earlier expiration upon the termination of the Reporting Person's service with the Company.

Intersect ENT, Inc.

Report date May 07, 2019 · Filed May 08, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	43,836	Reported balance After 2019-05-07 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2019-05-07 · Grant · Acquired 11,952 · Balance 43,836 F1: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest on December 31, 2019. F2: Includes 35,952 Restricted Stock Units.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest on December 31, 2019.

F2: Includes 35,952 Restricted Stock Units.

Minerva Neurosciences, Inc.

Report date September 27, 2023 · Filed September 29, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2033-09-26	Direct	12,500	Reported balance After 2023-09-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-09-27 · Grant · Acquired 12,500 · Balance 12,500 F1: This option is granted to non-employee directors in accordance with the Company's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 12,500 shares of common stock per year. F2: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following September 27, 2023 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option is granted to non-employee directors in accordance with the Company's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 12,500 shares of common stock per year.

F2: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following September 27, 2023 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.

NovoCure Ltd

Report date June 03, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	25,471	Reported balance After 2026-06-03 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-03 · Grant · Acquired 11,610 · Balance 25,471 F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.15 · Expires 2036-06-03	Direct	16,999	Reported balance After 2026-06-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-03 · Grant · Acquired 16,999 · Balance 16,999 F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Omada Health, Inc.

Report date October 05, 2026 · Filed October 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	27,869	Reported balance After 2026-10-05 transaction · row 1 1 source row Row 1 · 2026-10-05 · Grant · Acquired 1,214 · Balance 27,869 F1: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program.

SI-BONE, Inc.

Report date June 04, 2026 · Filed June 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	43,772	Reported balance After 2026-06-04 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-04 · Grant · Acquired 10,957 · Balance 43,772 F1: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2: Includes 10,957 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date.

F2: Includes 10,957 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Talis Biomedical Corp

Report date March 16, 2021 · Filed March 18, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.60 · Expires 2031-03-15	Direct	35,112	Reported balance After 2021-03-16 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-03-16 · Grant · Acquired 35,112 · Balance 35,112 F1: 1/36th of the shares subject to the option shall vest monthly over the three years from the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: 1/36th of the shares subject to the option shall vest monthly over the three years from the grant date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

HilleVax, Inc.

Report date September 17, 2025 · Filed September 17, 2025

Section 16 reporting ended · disclosed 2025-09-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-09-17 transaction · row 1 1 source row Row 1 · 2025-09-17 · Other · Disposed 59,224 · Balance 0 F1: In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right to receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the Cash Amount by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.

F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right to receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the Cash Amount by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 04, 2017 Filed Dec 5, 2017 17:33 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	12,833	$30.06	$385,812.60	Disclosure SEC source: 0001562180-17-003742 · primarydocument.xml · nonDerivative · entry 2 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.275, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document
December 04, 2017 Filed Dec 5, 2017 17:33 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	12,833	$11.12	$142,702.96	Disclosure SEC source: 0001562180-17-003742 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 06, 2017 Filed Nov 6, 2017 19:42 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	12,833	$0.00 Strike: $11.12	$0.00	Disclosure SEC source: 0001562180-17-003492 · primarydocument.xml · derivative · entry 3 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,833 Underlying: Common Stock · 12,833 shares Expires 2024-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest commencing June 4, 2014. 25% of the shares subject to the option vested on June 4, 2015 and 1/48th of the shares subject to the option vests monthly thereafter over three (3) years. Read SEC document
November 06, 2017 Filed Nov 6, 2017 19:42 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	12,833	$27.78	$356,528.97	Disclosure SEC source: 0001562180-17-003492 · primarydocument.xml · nonDerivative · entry 2 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $28.75, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document
November 06, 2017 Filed Nov 6, 2017 19:42 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	12,833	$11.12	$142,702.96	Disclosure SEC source: 0001562180-17-003492 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 04, 2017 Filed Oct 5, 2017 16:03 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	12,833	$0.00 Strike: $11.12	$0.00	Disclosure SEC source: 0001562180-17-003210 · primarydocument.xml · derivative · entry 3 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,666 Underlying: Common Stock · 12,833 shares Expires 2024-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest commencing June 4, 2014. 25% of the shares subject to the option vested on June 4, 2015 and 1/48th of the shares subject to the option vests monthly thereafter over three (3) years. Read SEC document
October 04, 2017 Filed Oct 5, 2017 16:03 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	12,833	$29.96	$384,499.78	Disclosure SEC source: 0001562180-17-003210 · primarydocument.xml · nonDerivative · entry 2 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.40 to $30.325, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document
October 04, 2017 Filed Oct 5, 2017 16:03 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	12,833	$11.12	$142,702.96	Disclosure SEC source: 0001562180-17-003210 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 05, 2017 Filed Sep 6, 2017 17:23 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	12,833	$0.00 Strike: $11.12	$0.00	Disclosure SEC source: 0001562180-17-002847 · primarydocument.xml · derivative · entry 3 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,499 Underlying: Common Stock · 12,833 shares Expires 2024-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest commencing June 4, 2014. 25% of the shares subject to the option vested on June 4, 2015 and 1/48th of the shares subject to the option vests monthly thereafter over three (3) years. Read SEC document
September 05, 2017 Filed Sep 6, 2017 17:23 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	12,833	$31.05	$398,462.08	Disclosure SEC source: 0001562180-17-002847 · primarydocument.xml · nonDerivative · entry 2 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.95 to $31.35, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document
September 05, 2017 Filed Sep 6, 2017 17:23 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	12,833	$11.12	$142,702.96	Disclosure SEC source: 0001562180-17-002847 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 04, 2017 Filed Aug 7, 2017 16:38 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	12,833	$0.00 Strike: $11.12	$0.00	Disclosure SEC source: 0001562180-17-002607 · primarydocument.xml · derivative · entry 3 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,332 Underlying: Common Stock · 12,833 shares Expires 2024-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest commencing June 4, 2014. 25% of the shares subject to the option vested on June 4, 2015 and 1/48th of the shares subject to the option vests monthly thereafter over three (3) years. Read SEC document
August 04, 2017 Filed Aug 7, 2017 16:38 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	12,833	$29.00	$372,209.62	Disclosure SEC source: 0001562180-17-002607 · primarydocument.xml · nonDerivative · entry 2 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.73 to $29.35, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document
August 04, 2017 Filed Aug 7, 2017 16:38 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	12,833	$11.12	$142,702.96	Disclosure SEC source: 0001562180-17-002607 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 10, 2017 Filed Jul 12, 2017 17:07 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionStock Option (right to buy) · Derivative	12,835	$0.00 Strike: $11.12	$0.00	Disclosure SEC source: 0001562180-17-002468 · primarydocument.xml · derivative · entry 3 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,165 Underlying: Common Stock · 12,835 shares Expires 2024-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest commencing June 4, 2014. 25% of the shares subject to the option vested on June 4, 2015 and 1/48th of the shares subject to option vests monthly thereafter over three (3) years. Read SEC document
July 10, 2017 Filed Jul 12, 2017 17:07 UTC	Intersect ENT, Inc. XENT · Entity 127294	SaleCommon Stock	12,835	$27.18	$348,818.08	Disclosure SEC source: 0001562180-17-002468 · primarydocument.xml · nonDerivative · entry 2 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.45, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote on this Form 4. Read SEC document
July 10, 2017 Filed Jul 12, 2017 17:07 UTC	Intersect ENT, Inc. XENT · Entity 127294	Exercise / conversionCommon Stock	12,835	$11.12	$142,725.20	Disclosure SEC source: 0001562180-17-002468 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 18, 2017 Filed Jan 20, 2017 19:43 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantStock Options (Right to buy) · Derivative	70,000	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001562180-17-000300 · primarydocument.xml · derivative · entry 2 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2027-01-17 F2 · derivative.exercise_date: 1/8th of the shares subject to the option vest on July 1, 2017 and 1/48th of the total shares subject to the option vest monthly thereafter over 42 months. Read SEC document
January 18, 2017 Filed Jan 20, 2017 19:43 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantCommon Stock	15,000	$0.00	$0.00	Disclosure SEC source: 0001562180-17-000300 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · security: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest in equal annual installments over three years commencing on January 1, 2017. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.